Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
No one on the platform currently holds OLK.
No tracked institution reports a position in OLK as of their last filing.
No one on the platform has traded OLK yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
@Lexy911 also noteworthy that PPD (the clinical trial research arm running our ARDS trial) is a wholly owned subsidiary of $TMO Thermo Fischer Our head of investor relations Jan Medina was most recently running investor relations for $OLK. He left $OLK to join Inflarx after he successfully participated in negotiations of a buyout of Olink by Thermo over 150% premium ($10 to $26). A very well connected individual with noted experience as analyst, biotech expert, M&A, and capital markets. Good addition to inflarx.
View on StockTwits ↗
@Nelsin 525 is the low. My target is 615 by 08/30. I think it's setting up for a monster August. Newly declared dividend and $OLK acquisition haven't been fixed into the price yet. Crossing my fingers they also announce a buyback
View on StockTwits ↗
$UNH, $TMO & $ELF are earning giants. Pay attention to $ELF Monday morning as it slides back to 202-205 and hopefully 198-200. Always a great idea to buy calls in that range. Follow it's patterns closely and you'll see why it's the gift that keeps on giving. $UNH earnings Tuesday morning. Despite the recent pop, I still see another 8-10% upside. $TMO is my monster for the summer. Biggest medical technology company in the world with tremendous upside for years to come. Newly declared cash dividend and $OLK acquisition will send it to the moon with a +12-15%. These are my monsters this month. I know we all love the mag 7 but these companies will provide a more bang for your buck in my opinion. Research and trade carefully. Predictions for 08/30 $ELF 240-250 $UNH 580-600 $TMO 590-625
View on StockTwits ↗$TSLA while you're all fighting over this disaster, I'll drop you an earnings giant. $TMO is going to explode. It's my big bull of the month. 12%-15% upside. Declared a quarterly cash dividend after close today and acquired $OLK two days ago. Monster of a stock. Check it out and trade carefully.
View on StockTwits ↗
$OLK trade halt (T12) was alerted to our Members at 7:50pm EDT. Halt price: $26.02 Vol: 1.89M.
View on StockTwits ↗
It's done, $TMO has been cleared to acquire Swedish biotech company $OLK. That's a +6.4% return / +16.2% annualized return for me and win 4/4 on merger arb deals. Merger arbitrage is a great strategy if you pick reasonable deals and be patient 👌
View on StockTwits ↗
$OLK $TMO - Tender Offer Expires @ 5pm MergerBrief.com
View on StockTwits ↗
$OLK Olink Announces Receipt of CMA Clearance for Proposed Acquisition by Thermo Fisher https://www.stocktitan.net/news/OLK/olink-announces-receipt-of-cma-clearance-for-proposed-acquisition-by-pq8a3vk6lms4.html
View on StockTwits ↗
$OLK German regulators clear the acquisition by $TMO. UK CMA decision still pending after phase I investigation.
View on StockTwits ↗
Signal alert: $OLK - Overbought Trend Short (Overvalued) https://stockinvest.us/l/SEi58VNbg9
View on StockTwits ↗$OLK Researchers Use Olink® Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before Diagnosis https://www.stocktitan.net/news/OLK/researchers-use-olink-r-explore-to-identify-circulating-proteins-xlyittslgge1.html
View on StockTwits ↗
$OLK reported a loss of $0.13, consensus was ($0.12) via @eWhispers #epsmiss http://eps.sh/d/olk
View on StockTwits ↗
$OLK Olink reports Q1 EPS (13c), consensus (15c) Reports Q1 revenue $28.8M, consensus $30.22M.
View on StockTwits ↗$OLK Olink reports first quarter 2024 financial results https://www.stocktitan.net/news/OLK/olink-reports-first-quarter-2024-financial-8zzl5v9aaxi4.html
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $282M | +22.5% | $0.05 | $0.05–$0.05 | 521.6× | 1 |
| 2027 | $341M | +21.2% | $0.23 | $0.23–$0.23 | 113.4× | 1 |
| 2028 | $406M | +19.0% | $0.43 | $0.43–$0.43 | 60.7× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2024-08-14 | $-0.11 | $-0.07 | +36.4% |
| 2024-05-13 | $-0.12 | $-0.13 | -8.3% |
| 2024-03-25 | $0.14 | $-0.06 | -142.9% |
| 2023-11-15 | $-0.08 | $-0.01 | +87.5% |
| 2023-08-09 | $-0.09 | $-0.07 | +22.2% |
| 2023-05-11 | $-0.12 | $-0.11 | +8.3% |
| 2023-02-21 | $0.01 | $0.05 | +525.0% |
| 2022-11-10 | $-0.12 | $-0.01 | +91.7% |
| $2.9B |
| — |
| MORFMorphic Holding, Inc. | $56.99 | +0.04% | $2.9B | — |
| ONEM1Life Healthcare, Inc. | $16.47 | +0.00% | $3.4B | — |
Source: Financial Modeling Prep · peers by sector/industry